Hypothesis

Circadian clock proteins in entorhinal cortex (EC) layer II directly regulate the activity of kinesin‑1 motor complexes, thereby controlling the axonal transport of tau protein. When circadian timing is intact, kinesin‑1 activity is restricted to specific phases that favor anterograde transport of soluble tau toward synaptic terminals for degradation, whereas misaligned clock signaling sustains kinesin‑1 activity during inappropriate phases, promoting retrograde tau accumulation, seeding, and spread.

Rationale

• EC layer II grid cells exhibit high metabolic demand and rely on precise microtubule‑based transport for spatial coding (2).
• Tau pathology begins in these neurons where low calbindin and heightened kinase activity create a vulnerable environment (1).
• Circadian disruption activates GSK3β and CDK5, increasing tau phosphorylation (4).
• Recent work shows that BMAL1/CLOCK can transcriptionally repress KIF5B (kinesin‑1 heavy chain) via E‑box elements, a mechanism not yet examined in EC neurons.

Novel Mechanistic Insight

We propose that the core circadian heterodimer BMAL1:CLOCK binds to promoter regions of KIF5B and KIF5C in EC layer II, generating a rhythmic repression of kinesin‑1 expression that peaks during the subjective night. This temporal gating ensures that tau-loaded vesicles are moved anterogradely only when lysosomal activity and glymphatic clearance are maximal. Loss of BMAL1 binding (e.g., via clock gene knockdown or chronic jet‑lag) lifts this repression, causing constitutive kinesin‑1 activity, misdirection of tau cargo toward the soma, and increased retrograde transport that fuels seeding.

Testable Predictions

1. Molecular – In wild‑type mice, Kif5b mRNA and protein levels in EC layer II will show a ~24‑hour oscillation antiphase to Bmal1; arrhythmic mice (Bmal1 KO) will lose this rhythm and display elevated kinesin‑1 protein.
2. Cellular – Live‑imaging of tau‑eGFP in EC slices will reveal increased retrograde tau vesicle velocity during circadian misalignment (constant light) compared with normal light‑dark cycles.
3. Pathological – Mice with EC‑specific Bmal1 deletion will develop higher phospho‑tau burden in layer II at 3 months, preceding hippocampal pathology, despite identical sleep totals.
4. Rescue – Pharmacological enhancement of BMAL1 activity (e.g., REV‑ERBα antagonism) or timed optogenetic stimulation of SCN‑EC projections will restore kinesin‑1 rhythmicity, reduce retrograde tau flux, and attenuate seeding.

Experimental Approach

• Use Bmal1 floxed mice crossed with Wfs1‑Cre to target EC layer II. Verify knockout efficacy via qPCR and immunohistochemistry.
• Monitor sleep‑wake patterns with EEG/EMG to ensure total sleep duration remains unchanged between groups.
• Quantify kinesin‑1 levels via Western blot at 4‑hour intervals across a 24‑hour cycle.
• Perform ex vivo time‑lapse imaging of tau‑eGFP transport in EC slices treated with nocodazole to isolate microtubule‑dependent movement.
• Assess pathology using AT8 immunostaining and thioflavin‑S staining at 1, 3, and 6 months.
• Apply REV‑ERBα antagonist (SR8278) in drinking water on a timed schedule (ZT0‑ZT12) to test pharmacological rescue.

Falsifiability

If EC‑specific Bmal1 loss does not alter kinesin‑1 rhythmicity, tau transport directionality, or early tau accumulation, the hypothesis would be refuted. Conversely, observing the predicted molecular, cellular, and phenotypic changes would support the circadian gating of kinesin‑1 as a critical firewall preventing tauopathy initiation in the entorhinal cortex.